Rocket Pharmaceuticals (RCKT) Cash from Investing Activities (2015 - 2026)

Rocket Pharmaceuticals has reported Cash from Investing Activities for 12 years, with the latest figure at $17.4 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 130.06% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.2 million (up 363.93% YoY) and the FY2025 annual result came in at $103.8 million, down 21.21% from the prior year.
• Cash from Investing Activities retreated to $17.4 million in Q1 2026 per RCKT's latest filing, from $36.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $93.6 million in Q3 2025 and troughed at -$140.8 million in Q4 2023.
• A 5-year average of $5.0 million and a median of $31.2 million in 2023 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 229.01% in 2022, down 743.89% in 2022.
• Over 5 years, Cash from Investing Activities stood at -$108.6 million in 2022, then declined by 29.67% to -$140.8 million in 2023, then surged by 73.1% to -$37.9 million in 2024, then surged by 196.18% to $36.4 million in 2025, then tumbled by 52.1% to $17.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $17.4 million, $36.4 million, and $93.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.